N?-(?-acetoximinoalkyl)diazene-N-oxides and some of their transformations
摘要:
Nitroso compounds of the aromatic and aliphatic series react with O-acetylalkanoylamidoximes in the presence of dibromoisocyanurate, forming the previously unknown N'-(alpha-acetoximinoalkyl)diazene-N-oxides, which under gaseous NH3 or oxalic acid in methanol lose the acetyl group and as a result are transformed into the previously unknown N'-(alpha-hydroximinoalkyl)diazene-N-oxides.
Construction of 3,5-substituted 1,2,4-oxadiazole rings triggered by tetrabutylammonium hydroxide: a highly efficient and fluoride-free ring closure reaction of O-acylamidoximes
Tetrabutylammonium hydroxide (TBAH) is an efficient and mild alternative to tetrabutylammonium fluoride (TBAF) for base catalyzed cyclizations of 1,2,4-oxadiazoles from O-acylamidoximes. For most 3,5-substituted 1,2,4-oxadiazoles the reactions were dramatically accelerated by addition of 0.1 equiv of TBAH at room temperature. This method was also more generally applicable allowing for a wider range
LUKYANOV, O. A.;SALAMONOV, YU. B.;BASS, A. G.;STRELENKO, YU. A., IZV. AN CCCP. CEP. XIM.,(1991) N, S. 109-114
作者:LUKYANOV, O. A.、SALAMONOV, YU. B.、BASS, A. G.、STRELENKO, YU. A.
DOI:——
日期:——
FARNESOID X RECEPTOR AGONISTS AND USES THEREOF
申请人:Metacrine, Inc.
公开号:US20200131129A1
公开(公告)日:2020-04-30
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.
[EN] FARNESOID X RECEPTOR AGONISTS AND USES THEREOF<br/>[FR] AGONISTES DU RÉCEPTEUR FARNÉSOÏDE X ET LEURS UTILISATIONS
申请人:METACRINE INC
公开号:WO2018170173A1
公开(公告)日:2018-09-20
Described herein are compounds that are farnesoid X receptor agonists, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with farnesoid X receptor activity.